Evidence map›Paper›PMID 33859327›Full record

ArticleScientific reports2021

Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.

Shulan Tian, Henan Zhang, Pan Zhang, Michael Kalmbach, Jeong-Heon Lee, Tamas Ordog, Paul J Hampel, Timothy G Call, Thomas E Witzig, Neil E Kay and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Shulan TianDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. tian.shulan@mayo.edu.
Henan ZhangDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Pan ZhangDivision of Information Management and Analytics, Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
Michael KalmbachDivision of Information Management and Analytics, Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
Jeong-Heon LeeDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Tamas OrdogDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Paul J HampelDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Timothy G CallDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Thomas E WitzigDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Neil E KayDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Eric W KleeDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Susan L SlagerDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Huihuang YanDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Wei DingDivision of Hematology, Mayo Clinic, Rochester, MN, USA. Ding.Wei@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
Targeting Akt Activation in CLLK23CA160345 · NCI · MAYO CLINIC ROCHESTER · PI DING, WEI · 2011 to 2015
$837k
NCI NIH HHS K23 CA160345NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

T cell prolymphocytic leukemia (T-PLL) is a rare disease with aggressive clinical course. Cytogenetic analysis, whole-exome and whole-genome sequencing have identified primary structural alterations in T-PLL, including inversion, translocation and copy number variation. Recurrent somatic mutations were also identified in genes encoding chromatin regulators and those in the JAK-STAT signaling pathway. Epigenetic alterations are the hallmark of many cancers. However, genome-wide epigenomic profiles have not been reported in T-PLL, limiting the mechanistic study of its carcinogenesis. We hypothesize epigenetic mechanisms also play a key role in T-PLL pathogenesis. To systematically test this hypothesis, we generated genome-wide maps of regulatory regions using H3K4me3 and H3K27ac ChIP-seq, as well as RNA-seq data in both T-PLL patients and healthy individuals. We found that genes down-regulated in T-PLL are mainly associated with defense response, immune system or adaptive immune response, while up-regulated genes are enriched in developmental process, as well as WNT signaling pathway with crucial roles in cell fate decision. In particular, our analysis revealed a global alteration of regulatory landscape in T-PLL, with differential peaks highly enriched for binding motifs of immune related transcription factors, supporting the epigenetic regulation of oncogenes and genes involved in DNA damage response and T-cell activation. Together, our work reveals a causal role of epigenetic dysregulation in T-PLL.

Indexed as

Cellular ReprogrammingDNA Copy Number VariationsDNA DamageEpigenesis, GeneticGenome-Wide Association StudyHumansLeukemia, Prolymphocytic, T-CellLymphocyte ActivationT-LymphocytesTranscription, GeneticWnt Signaling Pathway

Identifiers

PMID33859327
PMCPMC8050249
OpenAlexW3153308779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.